1. Home
  2. RNTX vs GNTA Comparison

RNTX vs GNTA Comparison

Compare RNTX & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.71

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Logo Genenta Science S.p.A.

GNTA

Genenta Science S.p.A.

HOLD

Current Price

$1.31

Market Cap

69.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
GNTA
Founded
2001
2014
Country
United States
Italy
Employees
10
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
69.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RNTX
GNTA
Price
$0.71
$1.31
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
396.6K
59.3K
Earning Date
05-15-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.55
52 Week High
$2.18
$10.00

Technical Indicators

Market Signals
Indicator
RNTX
GNTA
Relative Strength Index (RSI) 31.69 41.66
Support Level N/A $1.30
Resistance Level $1.32 $1.70
Average True Range (ATR) 0.08 0.14
MACD -0.01 -0.03
Stochastic Oscillator 6.72 22.00

Price Performance

Historical Comparison
RNTX
GNTA

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About GNTA Genenta Science S.p.A.

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.

Share on Social Networks: